The inactivation of this channel contributes to glioblastoma cells’ resistance to radiation, implying that reactivating the BK channel could enhance therapeutic outcomes, positioning cilostazol as a potential repurposed therapy for GBM [25]. The gene discussed is KCNMA1; the disease is glioblastoma.